CSIMarket
 
Dyadic International Inc  (DYAI)
Other Ticker:  
 
 
Price: $1.5000 $-0.02 -1.316%
Day's High: $1.62 Week Perf: 2.74 %
Day's Low: $ 1.50 30 Day Perf: 16.28 %
Volume (M): 60 52 Wk High: $ 2.40
Volume (M$): $ 89 52 Wk Avg: $1.75
Open: $1.54 52 Wk Low: $1.19



 Market Capitalization (Millions $) 43
 Shares Outstanding (Millions) 29
 Employees 84
 Revenues (TTM) (Millions $) -645
 Net Income (TTM) (Millions $) 2,482
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Dyadic International Inc
Dyadic International Inc.
(DYAI) is a biotechnology company based in Jupiter, Florida, USA.
It specializes in developing and implementing advanced technology solutions for the discovery, development, and production of biologics such as vaccines, monoclonal antibodies, and biosimilars.
Dyadic's technology platform is based on its proprietary C1 gene expression technology which is capable of producing high levels of proteins and enzymes at a low cost.
The C1 platform is scalable, adaptable and has numerous applications in various industries including biopharmaceuticals, animal health, industrial enzymes, and biofuels.
Dyadic has established collaborations with several leading global biotech and pharmaceutical companies to develop and produce a wide range of biologics.
The company is also engaged in research and development to enhance its technology platform and expand its applications.
In addition to its biotechnology operations, Dyadic is also exploring opportunities in other related fields, including developing sustainable and environmentally-friendly products that are derived from its C1 technology.
Dyadic International Inc.
was founded in 1979 and went public in 2005.
The company has a team of over 90 employees and is led by CEO Mark Emalfarb.
It trades on the NASDAQ under the ticker symbol DYAI.


   Company Address: 1044 North U.S. Highway One, Suite 201 Jupiter 33477 FL
   Company Phone Number: 743-8333   Stock Exchange / Ticker: NASDAQ DYAI
   DYAI is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Dyadic Announces $60 Million Private Placement to Drive Revenue Growth and Commercialization Efforts

Published Mon, Mar 11 2024 12:30 PM UTC

Dyadic Announces $6.0 Million Private Placement to Drive Revenue Growth and Commercialization Efforts
JUNIPER, Fla., March 11, 2024 - Dyadic International, Inc. (Dyadic or the Company), a pioneer in biotechnology, has made a significant move towards accelerating its revenue growth and commercialization efforts. The Company recently closed a private placement of $6.0 mill...

Partnership

Collaborative Efforts by Dyadic International to Develop Affordable Rabies Prophylactics and Enhance Biomanufacturing Quality Assurance

Published Wed, Feb 28 2024 1:30 PM UTC

Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, has recently made significant strides in its mission to provide accessible and affordable biopharmaceutical products for human and animal health. Through strategic partnerships and research collaborations, Dyadic aims to develop efficient rabies prophylactics and vaccines using its innovative C1 Cell...

Partnership

Dyadic and IIBR Join Forces to Combat Emerging Diseases and Bio-Threats, Paving the Way to a Safer Future

Published Fri, Feb 23 2024 7:00 AM UTC

DYADIC AND ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH COLLABORATE TO TACKLE BIO-THREATS AND EMERGING DISEASE SOLUTIONSJupiter, Fla. and Nes-Ziona, Israel, Feb. 23, 2024 - Dyadic International, Inc. (NASDAQ: DYAI), a renowned global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction, has announced an expanded collaborati...

Product Service News

Dyadic International and Israel Institute for Biological Research Collaborate to Combat Emerging Diseases and Bio-Threats

Published Wed, Feb 21 2024 1:30 PM UTC

Dyadic International, Inc. (Dyadic), a renowned biotechnology company specializing in advanced microbial platforms, and the Israel Institute for Biological Research (IIBR) have recently announced the advancement of their collaboration to target emerging disease solutions. This partnership aims to combine Dyadic's expertise in microbial platforms for protein bioproduction wit...

Partnership

Evolving Biomanufacturing Quality Assurance: Dyadic and Cygnus Technologies Introduce Game-Changing C1 HCP ELISA Kit

Published Tue, Feb 13 2024 1:30 PM UTC

Enhancing Quality Assurance in Biomanufacturing: Dyadic and Cygnus Technologies Partner to Provide C1 HCP ELISA AssayDyadic International Inc. (Dyadic) and Cygnus Technologies, part of Maravai LifeSciences, have recently joined forces in a strategic partnership to improve the quantification of Host Cell Proteins (HCP) in biomanufacturing processes. This collaboration aims to...






 

Dyadic International Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com